OPKO Health Q3 Earnings Ahead Of Expectations

  • OPKO Health Inc OPK reported Q3 revenues were down 10% Y/Y to $385.8 million, beating the consensus of $302.27 million.
  • Revenue from diagnostic services decreased to $340.1 million from $382.5 million, primarily due to a decrease in COVID-19 testing volume, partially offset by an improvement in COVID-19 test reimbursement and an increase in clinical and genomic test revenue.
  • The Company reported EPS of $0.04, beating the consensus loss of $(0.01).
  • During Q3, OPKO subsidiary BioReference Laboratories processed 2.2 million COVID-19 PCR tests and 158,100 COVID-19 serology tests.
  • Guidance: OPKO CFO Adam Logal said on the earnings call that the firm expects to perform between 1.7 million and 2.1 million COVID-19 tests in Q4 FY21.
  • Assuming the base business will remain at current levels, Logal said that OPKO expects overall revenues of $290 million - $320 million in Q4 FY21, with revenue from services of $250 million - $280 million, and revenues from products of $32 million - $36 million.
  • Price Action: OPK shares are up 3.54% at $3.80 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!